New Allergy Drug Gets Preliminary FDA Approval

Monday, 09 Dec 2013 04:10 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
An oral immunotherapy aimed at grass and pollen allergies has a benefit and safety profile that supports its approval, according to briefing documents posted on Monday by the U.S. Food and Drug Administration ahead of a meeting by outside experts to discuss the drug.

Oralair, made by France's Stallergenes SA, would be the first such licensed therapy in the United States. It has been in use in Europe for several years.

The documents were posted prior to a meeting on Wednesday of an FDA advisory committee meeting that will provide a recommendation on whether the drug merits U.S. approval. The FDA considers advisory panel views when it decides whether to approve a drug, but is not obligated to follow its recommendation.

The FDA committee documents said that several large studies in Europe and the United States showed that the drug's efficacy was "robust" and "consistent." The documents said the treatment was "generally well-tolerated."

On Thursday, the committee will meet to discuss Grastek, an oral treatment for grass allergies that would be sold by Merck & Co. In Europe, Merck's partner, Danish company ALK Abello, sells the product as Grazax.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

94 Percent of US Hospitals Unprepared for Ebola

Friday, 24 Oct 2014 16:28 PM

Only about 6 percent of American hospitals have infection control procedures in place to effectively and safely handle E . . .

Osteoporosis Screening Misses Many At Risk: Study

Friday, 24 Oct 2014 16:22 PM

Current osteoporosis screening guidelines and tools fail to identify many younger postmenopausal women at risk for osteo . . .

9 Deadliest Viruses on Earth

Friday, 24 Oct 2014 16:19 PM

A new ranking of the world's deadliest viruses finds flu and Ebola rank among the rogue's gallery of world's nastiest pa . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved